Details for Patent: 11,857,543
✉ Email this page to a colleague
Which drugs does patent 11,857,543 protect, and when does it expire?
Patent 11,857,543 protects VAFSEO and is included in one NDA.
This patent has ninety-two patent family members in forty countries.
Summary for Patent: 11,857,543
| Title: | Compositions and methods for treating anemia |
| Abstract: | Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS. |
| Inventor(s): | Robert Shalwitz, Charlotte Hartman, Akshay Buch, Isaiah Shalwitz, John Janusz, Joseph Gardner |
| Assignee: | Akebia Therapeutics Inc |
| Application Number: | US14/897,849 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; Dosage form; |
Drugs Protected by US Patent 11,857,543
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akebia | VAFSEO | vadadustat | TABLET;ORAL | 215192-001 | Mar 27, 2024 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS | ⤷ Start Trial | ||||
| Akebia | VAFSEO | vadadustat | TABLET;ORAL | 215192-002 | Mar 27, 2024 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS | ⤷ Start Trial | ||||
| Akebia | VAFSEO | vadadustat | TABLET;ORAL | 215192-003 | Mar 27, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,857,543
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3007695 | ⤷ Start Trial | 301278 | Netherlands | ⤷ Start Trial |
| European Patent Office | 3007695 | ⤷ Start Trial | CA 2024 00026 | Denmark | ⤷ Start Trial |
| European Patent Office | 3007695 | ⤷ Start Trial | PA2024521 | Lithuania | ⤷ Start Trial |
| European Patent Office | 3007695 | ⤷ Start Trial | LUC00347 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 3007695 | ⤷ Start Trial | 2024C/524 | Belgium | ⤷ Start Trial |
| European Patent Office | 3007695 | ⤷ Start Trial | 24/2024 | Austria | ⤷ Start Trial |
| European Patent Office | 3007695 | ⤷ Start Trial | 122024000039 | Germany | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
